Aspen Pharmacare Holdings Limited (APNHY) Stock

About Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Aspen Pharmacare Holdings Limited is headquartered in ZA.

Aspen Pharmacare Holdings Limited (APNHY) stock trades at $8.59 with a market capitalization of $3.81B. The stock is valued at a price-to-earnings (P/E) ratio of -33.17, price-to-book of 0.82, price-to-sales of 1.73. Over the past 52 weeks the stock has ranged between $5.24 and $9.45, and currently trades 9.1% below its 52-week high. It pays a dividend yielding 1.40%.

On profitability, Aspen Pharmacare Holdings Limited generates a return on equity (ROE) of -2.41%, return on capital employed of 5.49%, an operating margin of 16.01%, a net profit margin of -5.19%.

Official website: www.aspenpharma.com